Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY)

Acerta Pharma logo

Acerta Pharma

Status and phase

Active, not recruiting
Phase 3


Chronic Lymphocytic Leukemia


Drug: Venetoclax
Drug: Obinutuzumab
Drug: Acalabrutinib
Drug: Chemoimmunotherapy

Study type


Funder types



2018-002443-28 (EudraCT Number)
D8221C00001 (Other Identifier)

Details and patient eligibility


The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL

Full description

This randomized, global, multicenter, open-label, Phase 3 study will evaluate the efficacy and safety of AV and AVG versus chemoimmunotherapy (FCR or BR) in subjects with previously untreated CLL without del(17p) or TP53. Subjects will be randomized in a 1:1:1 ratio into 3 arms through a block stratified randomization procedure. The study includes screening (35 days), treatment (from randomization until study drug discontinuation) and follow-up phase.


984 patients




18 to 130 years old


No Healthy Volunteers

Inclusion criteria

* Men and women ≥18 years of age. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Diagnosis of CLL that meets published diagnostic criteria (Hallek et al. 2018) * Active disease per IWCLL 2018 criteria that requires treatment. * Participants must use highly effective birth control throughout the study.

Exclusion criteria

* Any prior CLL-specific therapies. * Detected del(17p) or TP53 mutation. * Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL) (e.g., Richter's transformation, prolymphocytic leukemia \[PLL\], or diffuse large B cell lymphoma \[DLBCL\]), or central nervous system (CNS) involvement by leukemia. * History of confirmed progressive multifocal leukoencephalopathy (PML). * Received any investigational drug within 30 days before first dose of study drug. * Major surgical procedure within 30 days before the first dose of study drug. * Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 or 4 cardiac disease. Note: Subjects with controlled, asymptomatic atrial fibrillation are allowed to enroll on study. * Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach, or extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass. * Received a live virus vaccination within 28 days of first dose of study drug. * Known history of infection with human immunodeficiency virus (HIV). * Serologic status reflecting active hepatitis B or C infection. * History of known hypersensitivity or anaphylactic reactions to study drugs or excipients. * History of stroke or intracranial hemorrhage within 6 months before first dose of study drug. * Known bleeding disorders. * Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists. * Female participants must not be breastfeeding or pregnant. * Concurrent participation in another therapeutic clinical trial.

Trial design

Primary purpose




Interventional model

Parallel Assignment


None (Open label)

984 participants in 3 patient groups

Acalabrutinib, Venetoclax
Experimental group
Acalabrutinib in combination with Venetoclax
Drug: Acalabrutinib
Drug: Venetoclax
Acalabrutinib, Venetoclax, Obinutuzumab
Experimental group
Acalabrutinib in combination with Venetoclax with Obinutuzumab
Drug: Acalabrutinib
Drug: Obinutuzumab
Drug: Venetoclax
Active Comparator group
Chemoimmunotherapy FCR: Fludarabine, Cyclophosphamide and Rituximab BR: Bendamustine and Rituximab
Drug: Chemoimmunotherapy

Trial contacts and locations



Central trial contact

AstraZeneca Clinical Study Information Center

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems